Trial reportJournal of the National Cancer Institute. Monographs2012
Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?
Trial report in Journal of the National Cancer Institute. Monographs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Trial
- Delayed definitive management of localized prostate cancer: what do we know?Prostate cancer and prostatic diseases · 2025Review
- Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance.European urology open science · 2021Article
- PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.Journal of the National Comprehensive Cancer Network : JNCCN · 2019Article
- Prostate cancer: Combining endocrine treatment and radiotherapy: a bright future.Nature reviews. Urology · 2016Article
- Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?BioMed research international · 2016Review
- Effect of rTsP53 on the M1/M2 activation of bone-marrow derived macrophage in vitro.International journal of clinical and experimental pathology · 2015Article
- Prostate cancer: impact of national guidelines on brachytherapy monotherapy.Nature reviews. Urology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer and its management have been intensely debated for years. Recommendations range from ardent support for active screening and immediate treatment to resolute avoidance of screening and active surveillance. There is a growing body of level I evidence establishing a clear survival advantage for treatment of subsets of patients with clinically localized prostate cancer. This chapter presents a review of these randomized controlled trials. We argue that an understanding of this literature is relevant not only to those considering active surveillance but also to those evaluating the merits of screening. In addition, a number of important evidence-based conclusions concerning what should and should not be done can be gleaned from these trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.